<DOC>
	<DOCNO>NCT00703924</DOCNO>
	<brief_summary>This study determine effectiveness safety WR 279,396 , topical cream treatment cutaneous leishmaniasis . This study conduct placebo control double-blind condition local population group Tunisia leishmaniasis endemic .</brief_summary>
	<brief_title>Topical Treatment Cutaneous Leishmaniasis With WR 279,396 : A Phase 2 Study Old World</brief_title>
	<detailed_description>WR 279,396 paromomycin-based topical cream show suggestion effective treatment non-serious , non-complicated cutaneous leishmaniasis previous clinical study . The goal study expand observation large , rigorous study clearly define efficacy product collect information adverse effect . Subjects randomize receive either WR 279,396 vehicle placebo ; apply twice day 20 day .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>Age 575 year Lesions must measure least 1 cm primarily ulcerative Have cutaneous leishmaniasis prove parasitologically lesion select study Must give write informed consent participate study Known drug intolerance aminoglycosides patient immediate family Previous use antileishmanial drug ( within 3 month ) present use routinely nephrotoxic ototoxic drug Patients tuberculosis treatment Potential followup : le 7 month time remain present address and/or plan leave area 30 day Extent disease : 5 lesion lesion equal great 5 cm lesion le 5 cm eye , lesion face , opinion attend dermatologist could potentially cause significant disfigurement Location disease : mucosal involvement Disseminated disease : clinically significant lymphadenitis nodule painful great 1 cm size lymphatic drainage ulcer Concomitant medical problem : significant medical problem kidney liver determine history follow laboratory study : Hearing abnormality Ongoing pregnancy plan become pregnant Females child bearing age ( Tunisia Only ) Signs symptoms peripheral neuropathy Kidney : clinically significant abnormality urine analysis , serum level creatinine , BUN , total protein great upper limit normal laboratory . Liver : AST ALT great upper limit normal laboratory General : glucose , Na+ , K+ great upper limit normal laboratory</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cutaneous leishmaniasis topical treatment safety efficacy</keyword>
</DOC>